Day Two Agenda

7:00 am - 4:00 pm | Boston, MA

Want to see the agenda, speaker faculty and more all in one place? Download the full Event Guide.

7:00 am Registration

7:55 am Chair’s Opening Remarks

  • Jian Yan Vice President, Research & Discovery, Geneos Therapeutics

Novel Methods for Successful Neoantigen Identification & Real World Application

8:00 am Categorizing Most Effective Neoantigens to Ensure Greatest Clinical Benefits


  • Filtering the different neoantigen sub-categories
  • Sequencing the whole genome to identify neoantigens arising from genomic rearrangements
  • Identifying the different categories of antigens and rationalizing the most preferred subset

8:30 am Screening the RNA Space for Frameshift Neoantigens


  • Sharing an efficacy readout for a preventative cancer vaccine trial
  • Predicting before treatment, who will respond to immunotherapeutics and who will not

9:00 am Vaccination Against Shared Neoantigens Induced in Recurrent & Future Tumors

  • Eli Gilboa Professor - Microbiology & Immunology, School of Medicine , University of Miami


  • Common neoantigens are induced in disseminated tumor lesions and resident dendritic cells by targeted siRNA inhibition of the peptide transporter TAP
  • Using broadly applicable chemically synthesized oligonucleotides to vaccinate against induced neoantigens which inhibits tumor growth in recurrent and premalignant models
  • Vaccination against induced neoantigens will benefit the 70-80% of cancer patients that do not express or express too few mutation-derived neoantigens

9:30 am Identification of Novel pHLA Targets for Solid Tumor


  • Advantages of intracellular targets (pHLAs) versus viral, neoantigens or conventional cell surface antigens
  • Strategies to find the most prevalent and immunogenic pHLA targets in tumors of CPI responders
  • Selection of self-antigen targets with highest tumor vs normal ratios to avoid off-tumor, on-target toxicities of TCR based therapies

10:00 am Morning Break & Networking

Diving into the Second Wave of Immune Response Successes in Trials

10:30 am Session Reserved for Cayman Chemical

11:00 am Immune Camouflaging in Tumors: Implications for Neoantigen Vaccines


  • JanusMatrix™, integrated in the Ancer® neoantigen discovery platform, is a specialized in silico tool used to distinguish effector from inhibitory neoantigens
  • Ancer® analysis of tumors derived from nivolumab-treated melanoma patients reveals patterns consistent with immune camouflaging: lowered immunogenicity and increased tolerogenic signals
  • Relevant neoantigen targets may be harder to identify once patients are treated with checkpoint inhibitors. Neoantigen vaccines may be better administered prior to checkpoint inhibitor therapy

11:30 am Session Reserved for Adaptive Biotechnologies

12:00 pm Lunch & Networking

Combinations with Immune Checkpoint Inhibitors to Enhance Vaccine Effects

1:00 pm Insights into Combination Therapies of Neoantigens and Checkpoint Inhibitors for More Successful Cancer Cures


  • Showing what strategies have been developed in combination with checkpoint inhibitors
  • Discriminating the value of the vaccine versus the checkpoint inhibitor
  • Uncovering the best pre-clinical designs to address issues associated with early stage and late stage cancer

1:30 pm New Class of Antigen-Specific Cancer Active Immunotherapies based on an Off-the-Shelf Antigen Presenting Cell line (PDC*line)

  • Eric Halioua President & Chief Executive Officer, PDC*line Pharma


  • PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells
  • PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors
  • Applying the technology for any cancer

2:00 pm Neoantigen Based Monoclonal Antibodies in Combination with Checkpoint Inhibitors

  • Philip Arlen President & Chief Executive Officer, Precision Biologics


  • Identifying tumor neoantigens
  • Determining the function of antibodies targeting the neoantigens
  • Justification for combining with checkpoint inhibitors

2:30 pm Afternoon Break & Networking

Comparing Platform Approaches to Challenge Our Understanding & Decision Making

3:00 pm Roundtable Mastermind Session – Weighing the Pros & Cons of Different Methods to Prosecute Neoantigen Targets


  • Comparing the various approaches and platforms used to target neoantigens
  • Discussing different types of platforms including RNA, DNA or peptides as there is currently no real incentive to make a decision
  • Reviewing other therapies being developed for more successful identification
  • Challenge your thoughts on shared vs. individualized approaches

3:30 pm Ensuring Effective Cross-Presentation of Neoantigens to Induce a Broad & Strong CD8 T Cell Response


  • Optimize long-lasting delivery of neoantigens to dendritic cells
  • Cross-presentation of neoantigens to stimulate broad CD8 T cell responses
  • Correlation of immune responses and clinical responses

4:00 pm Chair’s Closing Remarks